FMA
ACHN

FNY Managed Accounts’s Achillion Pharmaceuticals ACHN Stock Holding History

FNY Managed Accounts’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-10,000
Closed -$75.7K – 230
2014
Q2 		$75.7K Buy
+10,000
New +$39.9K 0.28% 40

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FNY Managed Accounts's ACHN Position: Q3 2014 in Review

FNY Managed Accounts sold out of Achillion Pharmaceuticals (ACHN) in Q3 2014, closing a stake of 10,000 shares — an estimated $75.7K sold.

FNY Managed Accounts first reported a position in ACHN in Q2 2014 and held it in 1 quarter. The position peaked at $75.7K in Q2 2014. 161 funds tracked by Wall St. Rank hold ACHN as of Q3 2014.

  • FNY Managed Accounts reported no remaining Achillion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • FNY Managed Accounts sold 10,000 Achillion Pharmaceuticals shares in Q3 2014, an estimated $75.7K.
  • FNY Managed Accounts first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • FNY Managed Accounts's Achillion Pharmaceuticals position peaked at $75.7K in Q2 2014.
  • 161 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2014.

Based on FNY Managed Accounts's 13F filing for Q3 2014, filed 16 Oct 2014.